HURA
TuHURA Biosciences IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$93.78M
P/E Ratio
—
EPS
$-0.63
Beta
—
52W High
$4.44
52W Low
$0.41
50-Day MA
$1.38
200-Day MA
$1.95
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About TuHURA Biosciences Inc
TuHURA Biosciences Inc is a leading biotechnology firm focused on pioneering immunotherapy solutions aimed at revolutionizing cancer and autoimmune disease treatment. With a robust pipeline driven by extensive scientific research, the company is dedicated to unlocking the full potential of the human immune system to enhance patient outcomes significantly. TuHURA's strategic partnerships and commitment to innovative technologies position it well for sustainable growth and value creation in the fast-evolving biopharmaceutical sector. As it advances its research and development activities, TuHURA is set to be a transformative player in the future of healthcare.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-28.05M |
| Operating Margin | 0.00% |
| Return on Equity | -169.20% |
| Return on Assets | -74.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.35 |
| Price-to-Book | 3.86 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $63.58M |
| Float | $41.23M |
| % Insiders | 25.66% |
| % Institutions | 10.38% |
Analyst Ratings
Consensus ($8.62 target)
1
Strong Buy2
BuyData last updated: 4/8/2026